January 2025

Researchers at The University of Hong Kong have made an exciting discovery about how human cells protect DNA during cell division, offering new insights into combating diseases such as cancer. Led by Professor Gary Ying Wai CHAN from the School of Biological Sciences, Faculty of Science, and Professor Ken Hoi Tang MA from the Department of Pathology, LKS Faculty of Medicine, the research uncovers the vital role of a protein called PICH in preventing genetic errors that can lead to diseases such as cancer. Their findings were recently published in the journal Nucleic Acids Research.

The awards will be co-located with the 5th GMP and Quality Management 2025 conference scheduled for April 24th – 25th. Eminence Business Media acknowledges remarkable contributions and unwavering dedication in the industry, and this award ceremony serves as a distinguished platform to recognize and appreciate the unwavering dedication, innovation, and commitment of individuals and teams who have demonstrated exceptional performance in upholding the highest standards of quality, safety, and efficacy in pharmaceutical products.

IIHMR University, Jaipur, is organizing the Pradanya 2025 : Global Health Management Research Conference GHMRC 2025 on February 14-15, 2025, at our campus in Jaipur, India.

Post Graduate Degree in Pharmaceutical Sciences, Bio-Chemistry, Biotechnology, Chemistry, Pharmacology, Microbiology from a recognized University. or equivalent Associate-ship diploma of the Institution of Chemists; experience in Chemical/Physio-chemical testing and analysis of drugs in drugs testing laboratory under the Drugs and Cosmetics Act and Rules.

Basic & Translational Research in Cancer; Post graduation in M.Pharma, Life Sciences, Biotech, zoology, Botany with PG Diploma in Clinical Research-Mandatory. To work on project entitled Basic and Translational Research in Cancer.

Project entitled Development of human iPSCs derived 3D lung organoid as a model for Idiopathic pulmonary fibrosis disease : A potential preclinical platform for screening of anti-fibrosis drug and novel biomarker discovery. M.Sc. in Life Sciences, Biotechnology, Biochemistry, Molecular Biology

M.Sc. Biotechnology, Microbiology or relevant life sciences discipline with a minimum of 55% marks. Minimum experience of two years as researcher. Establishment of synthetic antibody engineering platform for rapid development of indigenous bispecific antibodies to debilitate zoonotic pathogens reducing their pandemic potential.

M.Pharm, MS Pharm, MSc or Equivalent with specialization in Biotechnology, Microbiology or Life sciences. Investigating of the role of LncRNA PANDAR in the progression and metastasis of ovarian cancer. Prior experience in basic techniques in Molecular Biology, Cell culture and Biochemistry are desirable but not mandatory.